高级检索
当前位置: 首页 > 详情页

Luteolin Inhibits Fibrillary beta-Amyloid(1-40)-Induced Inflammation in a Human Blood-Brain Barrier Model by Suppressing the p38 MAPK-Mediated NF-kB Signaling Pathways

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China [2]Key Laboratory of Uighur Medicine of Xinjiang Uygur Autonomous Region, Xinjiang Institute of Materia Medica, Urumqi 830004, China [3]Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China [4]National Clinical Research Center for Digestive Disease, Beijing 100050, China [5]Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing 100050, China
出处:
ISSN:

关键词: Alzheimer's disease amyloid-beta peptides cyclooxygenase-2 cytokine fibrillar amyloid-beta peptides luteolin mitogen-activated protein kinases nuclear factor kB blood-brain barrier

摘要:
Amyloid-beta peptides (A beta) exist in several forms and are known as key modulators of Alzheimer's disease (AD). Fibrillary A beta (fA beta) has been found to disrupt the blood-brain barrier (BBB) by triggering and promoting inflammation. In this study, luteolin, a naturally occurring flavonoid that has shown beneficial properties in the central nervous system, was evaluated as a potential agent to preserve barrier function and inhibit inflammatory responses at the BBB that was injured by fA beta(1-40). We established an in vitro BBB model by co-culturing human brain microvascular endothelial cells (hBMECs) and human astrocytes (hAs) under fA beta(1-40)-damaged conditions and investigated the effect of luteolin by analyzing cellular toxicity, barrier function, cytokine production and inflammation-related intracellular signaling pathways. Our results demonstrated that, in cells injured by fA beta(1-40), luteolin increased cell viability of hBMECs and hAs. The cytoprotection of the co-culture against the damage induced by fA beta(1-40) was also increased at both the apical and basolateral sides. Luteolin protected the barrier function by preserving transendothelial electrical resistance and relieving aggravated permeability in the human BBB model after being exposed to fA beta(1-40). Moreover, in both the apical and basolateral sides of the co-culture, luteolin reduced fA beta(1-40)-induced inflammatory mediator and cytokine production, including cyclooxygenase-2 (COX-2), tumor necrosis factor alpha (TNF-alpha), interleukin 1 beta (IL-1 beta), interleukin 6 (IL-6), and interleukin 8 (IL-8), however it did not show sufficient effects on scavenging intracellular reactive oxygen species (ROS) in hBMECs and hAs. The mechanism of BBB protection against fA beta(1-40)-induced injury may be related to the regulation of inflammatory signal transduction, which involves inhibition of p38 mitogen-activated protein kinase (MAPK) activation, downregulation of phosphorylated inhibitory kB kinase (phosphor-IKK) levels, relief of inhibitory kB alpha (IkB alpha) degradation, blockage of nuclear factor kB (NF-kB) p65 nuclear translocation, and reduction of the release of inflammatory cytokines. Moreover, the employment of p38 MAPK and NF-kB inhibitors reversed luteolin-mediated barrier function and cytokine release. Taken together, luteolin may serve as a potential therapeutic agent for BBB protection by inhibiting inflammation following fA beta(1-40)-induced injury.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类 | 3 区 化学
小类 | 3 区 有机化学
最新[2025]版:
大类 | 3 区 化学
小类 | 3 区 生化与分子生物学 3 区 化学:综合
JCR分区:
出版当年[2015]版:
Q2 CHEMISTRY, ORGANIC
最新[2023]版:
Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Q2 CHEMISTRY, MULTIDISCIPLINARY

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2015版] 出版当年五年平均[2011-2015] 出版前一年[2014版] 出版后一年[2016版]

第一作者:
第一作者单位: [1]Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
通讯作者:
通讯机构: [3]Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China [4]National Clinical Research Center for Digestive Disease, Beijing 100050, China [5]Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing 100050, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:817 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)